In 2018, Johnson & Johnson embarked on a mission to transform the way blood clots are studied. Their aim was to determine how various clot characteristics such as size, composition, and density could impact patient outcomes, as well as how two of the company’s medical devices fared in clot removal. To achieve this, they conducted a study that involved enrolling 1,000 stroke patients at 36 clinical trial sites around the world to analyze actual blood clots that had been removed from stroke patients.
The study, known as the Excellent Registry, is the largest acute ischemic stroke registry globally. It collects patient data, imaging, and clot information on a per-pass basis, with independent evaluators reviewing the data. This initiative highlights the company’s dedication to innovation in advancing stroke care. Given the alarming statistics that every 40 seconds someone in the United States has a stroke and every 3.5 minutes someone dies from one, Johnson & Johnson’s commitment to improving stroke care is crucial.
Johnson & Johnson’s latest study provides valuable insights into blood clots and their impact on patient outcomes. The study involved analyzing actual blood clots removed from stroke patients and collecting data on various clot characteristics such as size, composition, and density. The results showed that different clot characteristics can have a significant impact on patient outcomes. For example, larger clots were associated with increased risk of complications such as bleeding or re-occlusion of the vessel. Additionally, denser clots were found to be more resistant to thrombolysis (clot dissolution) than less dense ones.
Furthermore